---
title: "Genotype-Informed Intervention Research Workflow"
date: 2026-05-16
tags:
  - experimental-design
  - pharmacogenomics
  - genotype-stratified
  - quantification-ladder
  - workflow
  - mechanism-validation
related:
  - quantification-ladder.md
  - enzyme-quantification-protocol.md
  - abcg2-modulators.md
  - gout-genetic-variants.md
  - validation-experiments.md
  - uricase-abcg2-genotype-stratification-computational.md
status: research-framework
---

# Genotype-Informed Intervention Research Workflow

This framework tests whether genotype modifies an intervention's mechanism or response. It does not convert a variant into an intervention recommendation. A defensible study must confirm genotype, define a prospective interaction, characterize the research material and exposure, measure target engagement, and test a prespecified outcome.

## The closed loop

> **confirmed genotype → mechanistic prediction → characterized research material → measured exposure → target engagement → prespecified outcome → revise or falsify**

Genotype stratification cannot repair an unmeasured input. Conversely, batch characterization cannot establish a genotype interaction without an appropriate comparison group and functional readout.

## Five-step workflow

### 1. Define one genotype–mechanism interaction

State the molecular defect, the proposed intervention point, and the predicted direction before measuring an outcome. Keep established pharmacogenetics separate from discovery hypotheses.

| Variant context | Supported boundary | Open research question |
|---|---|---|
| **ABCG2 Q141K (rs2231142)** | Folding and trafficking defect; selected HDAC-inhibitor rescue conditions are demonstrated in vitro. PPARγ-mediated induction of wild-type ABCG2 is a separate mechanism. | Does a specified exposure change Q141K surface trafficking or functional urate flux relative to wild type? Direct rescue by butyrate is unvalidated. |
| **SLC22A12 loss-of-function variants** | Human loss of URAT1 function can produce renal hypouricemia and exercise-associated complications. | What degree and duration of partial target suppression preserves a usable safety margin? Human variants do not supply a dosing ceiling. |
| **HLA-B\*58:01** | Established allopurinol-hypersensitivity pharmacogenetic context. | Discovery interventions must pass their own efficacy and safety gates; they do not inherit comparative safety from avoiding allopurinol. |
| **G6PD deficiency** | Systemic recombinant uricase can cause severe hemolysis in susceptible patients. | Safety of any gut-local UOX configuration remains empirical; luminal location does not establish a safer product. |

Use clinical-grade genotyping for trial enrollment and confirm rare or high-consequence variants with an appropriate orthogonal method. Research arrays may generate hypotheses but cannot substitute for trial-grade confirmation.

### 2. Characterize the research material

Record exact composition, lot or batch identity, production route, storage, and relevant impurities. For biological material, identify the exact strain, construct, formulation, and containment conditions. For a chemical or extract, verify identity and potency with a matrix-appropriate analytical method.

Engineered UOX is research material, not a default intervention source. Each exact configuration must first be built and characterized in its intended host or material. Configuration-level comparison follows only after that evidence exists.

### 3. Verify exposure

Use the [`quantification-ladder.md`](./quantification-ladder.md) to calibrate a practical batch assay against an appropriate higher-specificity analytical method. Prespecify acceptance limits and how an exposure deviation changes analysis. An out-of-specification batch is documented or excluded under the protocol; it is not corrected through an unscripted exposure change.

Input potency, concentration in a sampled matrix, target-compartment exposure, and target engagement are distinct measurements. A certificate, stool metabolite result, or serum biomarker cannot substitute for the other links.

### 4. Measure target engagement

Choose a readout that distinguishes the proposed mechanism from adjacent explanations. Examples include transporter surface abundance, polarized urate flux, enzyme activity in the intended compartment, pathway-specific transcription, or a validated pharmacodynamic marker. Biomarker movement without target engagement is not mechanistic confirmation.

### 5. Test the genotype interaction

Use prespecified genotype strata, matched controls, blinded analysis where feasible, and a model or ethics-reviewed study appropriate to the evidence stage. Estimate the genotype-by-exposure interaction directly. Background therapy, diet, renal function, inflammation, and batch variation are covariates rather than post hoc explanations.

## Example: ABCG2 Q141K × candidate rescue exposure

A controlled study can compare wild-type, heterozygous, and homozygous Q141K epithelial models under a defined candidate exposure.

Required measurements:

1. Confirm ABCG2 genotype and comparable baseline expression.
2. Verify material identity, concentration, stability, and epithelial exposure.
3. Measure total and surface ABCG2 separately.
4. Measure basolateral-to-apical urate flux and include an ABCG2-inhibition control.
5. Test acute functional inhibition separately from chronic transcriptional or trafficking effects.
6. Advance only if surface trafficking and functional urate flux move coherently without an unacceptable off-target transporter effect.

The design tests a carrier-dependent mechanism; it does not assume that a fiber, butyrate, flavonoid, or chaperone exposure is beneficial.

## Example: ABCG2 genotype × luminal UOX

ABCG2 genotype can be a prospective stratification variable only after the UOX configuration itself is characterized. The sequence is:

1. Build and characterize each exact UOX configuration.
2. Compare configuration-level activity under the physiological factorial in [validation §1.33](./validation-experiments.md#133-physiological-uox-topology--oxygen--peroxide-factorial).
3. Test antioxidant loss, peroxide handling, and safety in [validation §1.36](./validation-experiments.md#136-luminal-urate-antioxidant-loss--uox-h2o2-safety-assay).
4. Only then design an appropriate genotype-stratified animal or ethics-reviewed human study.

COMP-019's unconditional flat-dose classification is not robust to COMP-044's tested substrate-occupancy and finite-window diagnostics. COMP-044 supplies no replacement dose, ΔSUA, genotype, physiological regime, efficacy, topology or chassis, production, or safety conclusion. Q141K therefore remains a prospective stratification variable, not a response predictor.

## Failure modes

- **Unverified input:** a null result cannot distinguish absent exposure from mechanism failure.
- **Mechanism substitution:** a downstream biomarker is treated as proof of transporter rescue or enzyme activity.
- **Post hoc stratification:** genotype groups are created after outcome inspection.
- **Evidence transfer:** safety or efficacy from a parent organism, approved drug, or adjacent genotype is assigned to a new material.
- **Single-axis interpretation:** renal function, inflammation, background therapy, or compartment-specific exposure is ignored.
- **Model overreach:** a computational classification is converted into a dose, clinical effect, or genotype ranking.

## Decision rule

A genotype-informed hypothesis advances only when material identity, exposure, target engagement, and the genotype interaction are all interpretable at the same evidence tier. Failure at one link redirects the next experiment; it does not become a carrier-specific recommendation.

## Cross-references

- [`gout-genetic-variants.md`](./gout-genetic-variants.md) — variant evidence catalogue
- [`abcg2-modulators.md`](./abcg2-modulators.md) — Q141K mechanisms and functional-assay requirements
- [`quantification-ladder.md`](./quantification-ladder.md) — material and batch characterization
- [`validation-experiments.md`](./validation-experiments.md) — configuration-level UOX and safety gates
- [`uricase-abcg2-genotype-stratification-computational.md`](./uricase-abcg2-genotype-stratification-computational.md) — superseded COMP-019 quantitative interpretation
- [`gut-lumen-uricase-physiologic-regime-computational.md`](./gut-lumen-uricase-physiologic-regime-computational.md) — COMP-044 scope and limits
